NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT03465540 2023-04-12Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesAmgenPhase 1 Terminated24 enrolled 21 charts
NCT02587598 2021-12-08Study of INCB053914 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated97 enrolled 40 charts
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT01908387 2015-07-28Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsCelgenePhase 1 Terminated2 enrolled
NCT00006019 2013-06-24Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerNational Cancer Institute (NCI)Phase 2 Completed